Cargando…
Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis
BACKGROUND: L-arginine is the common substrate for nitric oxide synthases and arginases. Increased arginase levels in the blood of patients with cystic fibrosis may result in L-arginine deficiency and thereby contribute to low airway nitric oxide formation and impaired pulmonary function. METHODS: P...
Autores principales: | Grasemann, Hartmut, Schwiertz, Raphael, Grasemann, Corinna, Vester, Udo, Racké, Kurt, Ratjen, Felix |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526723/ https://www.ncbi.nlm.nih.gov/pubmed/16764721 http://dx.doi.org/10.1186/1465-9921-7-87 |
Ejemplares similares
-
L-Ornithine Derived Polyamines in Cystic Fibrosis Airways
por: Grasemann, Hartmut, et al.
Publicado: (2012) -
Effect of Arginase Inhibition on Pulmonary L-Arginine Metabolism in Murine Pseudomonas Pneumonia
por: Mehl, Anne, et al.
Publicado: (2014) -
Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways
por: Martin, Isaac, et al.
Publicado: (2021) -
How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored?
por: Ben-Meir, Elad, et al.
Publicado: (2022) -
New Developments in Cystic Fibrosis Airway Inflammation
por: Palaniyar, Nades, et al.
Publicado: (2015)